GS-US-563-5925  Islend -1

A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF). EudraCT No. 2024-514046-37 

219816 VOGUE

A Phase 3b, multi-center, randomized, parallel group, open-label, non-inferiority study evaluating the efficacy, safety, and tolerability of oral dolutegravir/lamivudine once-daily as a first-line regimen compared to oral bictegravir/emtricitabine/tenofovir alafenamide oncedaily for virologic suppression and maintenance in antiretroviraltherapy naive adults living with HIV. EudraCT No. 2023-504993-40-00

MK-8591A-018

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in HIV-1-Infected Participants Virologically Suppressed on bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) EudraCT No. 2019-000587-23

MK-8591A-019

A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL, EudraCT 2019-000588-26

MK8591A-020

A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of MK-8591A Once-Daily in HIV-1 Infected Treatment-Naïve Participants, EudraCT 2019-000590-23

213500 SOLAR

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallelgroup, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alfenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed, EudraCT No. 2020‐002623‐11

FindHIV

Frühzeitige Identifikation mittels normierter Diagnosekriterien für die HIV-Infektion. (dagnä-Studie)

204862 TANGO

A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV 1 infected adults who are virologically suppressed. EudraCT No.:2015-004401-17

207966 ATLAS 2M

A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults who are Virologically Suppressed. EudraCT No.: 2017-002946-62

201585 ATLAS

A Phase III, randomized, multicenter, parallel-group, noninferiority,open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who arevirologically suppressed. EudraCT No.: 2016-001646-25

201584 FLAIR

A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants.  EudraCT No.: 2016-001646-25

GS-US-380-1490

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults. EudraCT No.: 2015-003988-10

AI438-047

A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1. EudraCT No.: 2014-002111-41

200056 LATTE-2

A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral regimen of GSK1265744 plus Abacavir/ Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects. EudraCT No.: 2013-000783-2 Last change: 07-JUL-2020

212483 Dynamic

A Phase IIb, randomized, double-blind, parallel-group study to assess the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegravir plus lamivudine in HIV-1 infected, treatmentnaïve adults, EudraCT: 2021-000016-28

CNAB 3002

A randomized, double-blind, comparative, parallel-group, multicentre trial to evaluate the safety and efficacy of 1592U89 versus placebo in combination with background antiretroviral therapy in HIV-infected antiretroviral therapy experienced subjects with CD4+ cell counts ≥ 100cells/mm³ and plasma viral load between 400 copies/ml and 50 000 copies/ml 1997

Peldesine 96-009

Phase I, placebo-controlled study of oral BCX-34 (Peldesine) 1998

Saquinavir SGC G5030 (Racing-Trial)

Pilot Study to evaluate the efficacy and safety of Saquinavir SGC in combination with Zidovudine and Zalcitabine and to optimize the sequence of two different antiviral triple regimes with respect to the development of resistance mutations in HIV-infected patients

M98-863

A randomized, double-blind, phase III study of ABT-378/Ritonavir plus Stavudine and Lamivudine vs. Nelfinavir plus Stavudine and Lamivudine in antiretroviral-naive HIV-infected subjects 1999

M98-888

A randomized, open-label, phase III study of ABT-378/Ritonavir in combination with Nevirapine and 2 nucleoside reverse transcriptase inhibitors (NRTIs) vs. Investigator selected protease inhibitor(s) in combination with Nevirapine and 2 NRTIs in antiretroviral-experienced HIV-infected subjects

MKC-301

A randomized double-blind comparison of MKC-442 versus placebo in antiretroviral-naive patients with HIV-1 RNA 5000 and 50000 copies/ml and CD4+ ³300 cells/mm³  who are initiating therapy with stavudine, lamivudine

DMP 266-006

Multizentrische, randomisierte, offene Phase III-Studie zum Vergleich der antiretroviralen Aktivität und Verträglichkeit drei verschiedener Kombinationstherapien bei HIV-infizierten Patienten (DMP-266 plus Indinavir, DMP-266 plus Zidovudin plus Lamivudin, Indinavir plus Zidovudin plus Lamivudin

DMP 266-027

Eine offene, randomisierte, multizentrische Studie der Phase II bei HIV-1 infizierten Patienten zur Bewertung der Sicherheit und Dauer der Virussuppression unter einer fortgesetzten Standardtherapie bestehend aus einem Protease-Inhibitor und zwei Nukleosidalen Reverse Transkriptase-Inhibitoren im Vergleich zu zwei neuen Therapieschemata, in denen entweder die Nukleosidalen Reverse Transkriptase-Inhibitoren oder der Protease-Inhibitoren durch DMP 266 ersetzt wird.

MKC-302

A randomized double-blind comparison of MKC-442 versus placebo in antiretroviral-naive patients with HIV-1 RNA >5000 and £300 000 copies/ml and CD4+ >300 cells/mm³ who are initiating therapy with stavudine, didanosine

MKC 502

An open-label extension study for patients on an emivirine containing regimen (roll over protocol for the MKC-301 and 302 being conducted in Europe)

APV 20001

A phase II randomised, multicenter, partially blinded, crossover study to assess the safety, tolerability, pharmacokinetics, and antiviral effect of two doses of GW433908 compared to Amprenavir (1200 mg bid) when given for 28 days to subjects infected with HIV-1

SU 5416.003

A multicenter, dose escalating study in patients with cutaneous AIDS-related Kaposi’s Sarcoma

SU 5416.301

A multicenter, open-Label, phase II study of the efficacy and saftety of SU5416 in patients with therapy refractory cutaneous AIDS-related Kaposi’s Sarcoma

DMP 266-053

Eine multizentrische, offene Phase III Studie zum Vergleich der antiretroviralen Aktivität, Verträglichkeit und Sicherheit von drei verschiedenen Kombinationstherapien bestehend aus: Efavirenz + Stavudine + Didanosin / Abacavir + NRTI + Lamivudin / Stavudin + Didanosin + Indinavir bei HIN-infizierten Patienten. Eine Folgestudie für die Studie DMP 266-006

NNR 20001

GW433908 vs. amprenavir

Switch

Ersatztherapie nach dreifach kombinierter Induktionstherapie zur Verlängerung des Netto-Therapieeffektes durch Verzögerung der Resistenzentwicklung bei HIV-1 infizierten Patienten (multizentrische, randomisierte, open-label Studie).

SILCAAT

A phase III, multicenter, randomized trial on the biological and clinical efficacy of subcutaneous, recombinant human Interleukin-2 in HIV infected patients with low CD4+ count by active, antiretroviral therapy 2000

Great Study

A randomized international, parallel group, open label comparison of the efficacy of second line antiretroviral therapy chosen based on best clinical judgment, or best clinical judgment plus HIV resistence genotyping supported by HIV Resistance Support Software interpretation, in HIV infected patients failing their first protease containing regime.

GF 9037 (Serostim)

A randomized, parallel group, double-blind, placebo-controlled, dose-ranging, multicenter study of recombinant human growth hormone (Serostim) in the treatment of HIV associated catabolism/wasting

DPC 083-201

A phase II, randomized, double-blind, dose-ranging study to assess the safety and tolerability of three doses of DPC 083 versus Efavirenz, in combination with open-label Zidovudine and Lamivudine, in antiretroviral-naive, HIV-1-infected subjects

GS-99-903 (Tenofovir)

A phase III randomized, double-blind, multicenter study of the treatment of antiretroviral-naive, HIV-1-infected patients comparing with Lamivudine and Efavirenz versus Stavudine, Lamivudine and Efavirenz

Saquinavir Pharmakokinetik

Comparative pharmacokinetics of twice-daily saquinavir administered as the soft gel capsule formulation or the hard gel capsule formulation in combination with ritonavir

APV 30002

A randomized, open label two arm trial to compare the safety und antiviral efficacy of GW 433908/Ritonavir to Nelfinavir BID when used in combination with Abacavir and Lamivudine BID for 48 weeks in antiretroviral therapy naive HIV-1 infected subjects

FTC-301

A randomized, double-blind, equivalence trial comparing Emtricitabine to Stavudine with a triple drug combination containing Didanosine plus Efavirenz in antiretroviral drug naive HIV-1 infected patients 2001

TORO 1 / TORO 2   RO 29-9800 T20-302/BV 16052

A phase III open-label, randomized, active, controlled study assessing the efficacy and saftey of T20 / Ro 29-9800 (HIV-1 fusion inhibitor) in combination with an optimized background regimen, versus optimized background regimen alone, in patients with prior experience and/or prior documented resistance to each of the three classes of approved antiretrovirals (nucleoside reverse transciptase inhibitors, non-nucleosids reverse transcriptase inhibitors and protease inhibitors)

BI 1182.6 (Tipranavir)

A phase IIa open-label multinational study of the effects of three dose pairs of Tipranavir/Ritonavir (b.i.d.) on the pharmacokinetic characteristics of protocol-defined, baseline, triple drug nucleoside and non-nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected subjects.

DPC 083-203

A Phase II randomized, double-blind, multicenter study to assess the safety and efficacy of two doses of  DPC 083, in combination with open-label Nucleoside Analog Reverse Transcriptase Inhibitors in HIV-1–infected subjects who are failing treatment with a non-nucleoside reverse transcriptase inhibitor-containing regimen

APV 30003

A phase III, randomized, multicenter, parallel group, open-label, three arm study to compare the efficacy and safety of two dosing regimes of GW433908/Ritonovir (700mg/100 mg twice daily or 1400mg/200mg once daily) versus Lopinavir/Ritonavir (400mg/100mg twice daily) for 48 weeks in protease inhibitor experienced HIV-infected Adults experiencing virological failure

CNA 30021 (Zodiac)

A phase III, 48-week, randomised, double-blind, multicenter study to evaluate the safety and efficacy of Abacavir 600 mg once-daily (QD) vs. Abacavir 300 mg BID in combination with Lamivudine 300 mg QD and Efavirenz 600 mg QD in antiretroviral therapy naive HIV-1 infected subjects

TMC125-C207

Efficacy of an 8-day treatment (7 days b.i.d. and 1 day o.d.) with 900mg TMC125 in HIV-1 positive subjects with phenotypically confirmed NNRTI resistance

GS-00-951 (Tenofovir EAP)

Eine offene Phase IIIb Studie zur Sicherheit und Verträglichkeit von Tenovovir Disoproxil Fumarat bei der Behandlung von HIV-infizierten Patienten mit begrenzten Behandlungsmöglichkeiten

BI 1100. 1359

Investigation of pharmacokinetic interaction of nevirapine and Methadon in HIV-infected patients under combination treatment with various NRTIs, phase IV

TMC114-C201

A phase IIa open, randomized trial to determine the antiviral activity in 60 HIV positive subjects with multiple PI resistant strains, receiving either control treatment or a daily dose of 800, 1600, 2400 or 3600 mg for 13 days followed by a single dose on day 14

AXDC-1(AXD455)

A phase-IIa repeat dose-rising study to explore the safety, efficacy and pharmakokinetics of intravenous AXD 455 doses in HIV-infected patients with multi-resistance or intolerable side effects on haart

DPC 083-303

A Phase III, randomized, double-blind, multicenter study to acess the safety and   efficacy of DPC 083 versus Nelfinavir in combination with AZT/3TC (i.e. Zidovudine and Lamivudine) in antiretroviral-naive HIV‑1‑infected subjects

TMC125-C203/ C209

A randomized, placebo-controlled phase II trial in HIV-1 infected, NRTI-, PI- and NNRTI-experienced subjects to evaluate the safety, tolerability and efficacy of different doses of TMC125 b.i.d. on top of an individually optimized antiretroviral therapy by means of a 3-stage dose-escalating design 2002

BI 1182.52 (Tipranavir)

A phase IIb double-blind, randomized, dose optimization trial of three doses of Tipranavir boosted with low dose Ritonavir (TPV/RTV) in multiple antiretroviral drug-experienced subjects.

TMC114-C207

A phase IIa open, randomized trial to determine the antiviral activity in HIV-1 positive subjects with multiple PI resistant strains, receiving either control treatment or TMC 114/Ritonavir treatment at various dosages for 13 days followed by a single dose on day 14

P00738-65 (PEG-Intron)

Klinische Prüfung der Phase 3 zu PEG-Intron bei intensiv behandelten HIV infizierten Patienten

CI-PSI-004-02-101 (Racivir)

A phase I study exploring the safety, tolerability, pharmacokinetics and virological effect of RCV after 14 days of oral ascending doses of 200, 400 and 600 mg RCV when used in combination with Efavirenz and Stavudine in HIV-infected men

APV 30005

An open-label phase III study to assess the long term safety profile of GW33908 containing regimens in HIV-1 infectect subjects

BI 1182.48 (RESIST-2)

Randomized, open-label, comparative safety and efficacy study of Tipranavir boosted with low-dose Ritonavir versus genotypically-defined Protease Inhibitor/Ritonavir in multiple antiretroviral drug-experienced patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir) 2003

BI 1182.17

A long-term open-label roll-over trial assessing the safety and tolerability of combination Tipranavir and Ritonavir use in HIV- infected subjects

BI 1182.51

An open label, randomized, parallel group pharmacokinetics trial of tipranavir / ritonavir (TPV/TRV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimized background regimen, in multiple antiretroviral (ARV) experienced patients

Kinesa

Simultaneous boosting of Nelfinavir and Saquinavir by small doses of Ritonavir: a pharmakokinetic study in HIV-infected patients

TMC114-C213

A phase II randomized, controlled (standard of care), partially blinded, 48-week trial to investigate dose response of TMC114/rtv in 3-class-experienced HIV-infected subjects 2004

TMC114-C215

An open-label trial of TMC114/rtv in HIV-1 infected, treatment experienced subjects

BI 1182.33

A phase IIb/III randomised, open label, active controlled trial to evaluate the antiviral efficacy and safety of treatment with 500 mg Tipranavir plus 100 mg or 200 mg Ritonavir p.o. BID in combination with standard background regimen in comparison to 400 mg Lopinavir plus 100 mg Ritonavir p.o. BID in combination with standard background regimen in antiretroviral therapy naïve patients for 48 weeks

INCB 8721 RVT-203 (Reverset)

A phase II placebo-controlled, double-blind, parallel dose group study exploring the safety, tolerability and virological effect of 50, 100 and 200 mg RVT in HIV-infected antiretroviral therapy-experienced subjects when used in combination with other antiretroviral agents

R27874-C202

A phase II, proof of principle, randomized, open-label trial in HIV-infected subjects with NNRTI experience and/or genotypic evidence of NNRTI resistance, who will receive R27874 once daily for 7 days in substitution for the NNRTI or PI in failing ART

TMC125-C141

A Phase I ,open-label, randomized, single dose, cross-over study to evaluate the relative bioavailability of 3 dose levels of TMC125 in HIV-1 infected subjects as a spray-dry formulation compared to the reference formulation TF035.

INCB 8721 DFC-901 (Reverset r-o)

A long-term open-label non-randomized study to evaluate the safety of 100 and 200 mg ReversetTM (RVT) in HIV-infected antiretroviral therapy-experienced subjects when used in combination with other antiretroviral agents 2005

A4001028

A multicenter, randomized, double-blind, placebo-controlled trial of a novel CCR5-antagonist, UK-427,857, in combination with OBT versus OBT alone for the treatment of antiretroviral-experienced HIV-1-infected subjects

A4001029 (Motivate)

A multicenter, randomized, double-blind, placebo-controlled trial of a novel CCR5-antagonist, UK-427,857, in combination with OBT versus OBT alone for the treatment of antiretroviral-experienced non CCR5-tropic HIV-1-infected subjects

CCR102881 (ASCENT)

A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW 873140 in combination with AZT/3TC (Lamivudine + Zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naïve adults

TMC125-C228

A Phase I randomized, open-label, multiple dose, cross-over trial in HIV-1 infected subjects to evaluate the relative bioavailability of TMC125 as a spray-dry formulation compared to the reference formulation TF035

TMC 278-C204

A phase IIb randomized, partially blinded, dose-finding trial of TMC278 in antiretroviral naïve HIV-1 infected subjects. EudraCT No. 2004-004055-19.

TMC114-C208

An open label trial of TMC114/rtv in HIV-1 infected subjects who were randomized in the trials TMC114-C201, -207 or in sponsor selected phase-I-trials

TMC114-C214

A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. EudraCT No. 2005-000594-22

TMC125-C229

An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks

TMC125-C216 (DUET 2)

A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options. [IND No. 63646] – A substudy of TMC125-C216 to evaluate the pharmacokinetic profile of TMC125, TMC114 and RTV at Week 4 and 24, co-administered with an individually optimized antiretroviral therapy 2006

TMC125-C217

An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216)

TMC 114-C211 (ARTEMIS)

A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/Ritonavir versus Lopinavir/Ritonavir in treatment-naive HIV-1 infected subjects. This trial will be referred to as ARTEMIS. EudraCT No. 2005-002486-36

AI 424-138 (CASTLE)

A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment Naïve Subjects

BI 1100.1452

A Case-Control Toxicogenomics Study to Identify Genetic Locus or Loci in Patients who have Experienced Symptomatic Hepatotoxicity and Severe Skin Rash within the First 8 weeks of Nevirapine Therapy. EudraCT No. 2005-004321-26

MK-0518-018 (BENCHMARK-1)

A multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and antiretroviral activity of MK-0518 in combination with an optimized background therapy (OBT) versus optimized background therapy alone, in HIV Infected patients with documented resistance to at least 1 drug in each of the 3 classes of licensed oral antiretroviral therapies. EudraCT No. 2005-005127-34.

BI 1100.1470 (ARTEN)

Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on same background, in HIV-1-infected patients who have received no previous antiretroviral treatment. EudraCT No. 2005-004330-40.

MK-0518 032-00

A randomized, double blind, two-armed trial to evaluate the efficacy and safety of MK-0518 versus LPV/RTV in patients with maximum suppression with LPV/RTV 2007

BI 1100.1498 (ERVIR)

Steady State Bioavailability of 2 different Viramune Extended Release formulations compared to steady state 400 mg of Viramune (200 mg BID) in HIV infected subjects, an open label, non randomized, multidose and multistage parallel group study.

ACH443-014A

A 14-Day, Randomized, Double-blind, comparative viral kinetic study of  Elvucitabine  versus Lamivudine administered  once daily to HIV-1 infected subjects with a documented M184V variant

ACH443-018

An open-label, 24-week extension study of Elvucitabine administered in combination with background antiretroviral agents in subjects who have completed 14 days of treatment in protocol ACH443-014A 2008

BI 1182.107

A multicenter, randomized, open label, clinical trial to evaluate three doses of tipranavir boosted with ritonavir (500 mg/200 mg qd, 250 mg/100 mg bid and 500 mg/100 mg bid) by assessing the steady-state pharmacokinetics and short-term efficacy and Safety in HIV-1 positive treatment naïve patients

BI 1100.1486 (Verxve)

A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD Nevirapine extended release formulation in comparison to 200 mg BID antiretroviral therapy naïve HIV-1 infected patients. EudraCT No. 2007-003654-29.

BI 1241.2

Safety, antiviral activity and pharmacokinetics of multiple oral doses of BI 207127 NA administered q8H for 5 days as monotherapy: a randomised, double-blind, placebo controlled study. EudraCT No. 2007-004068-38.

AVX-301

A phase 2b/3, randomized, double blind, dose confirming study of the safety, efficacy and tolerability of Apricitabine versus Lamivudine in treatment-experienced HIV-1 infected patients with the M184V/I mutation in reverse transcriptase. EudraCT No. 2007-003281-18.

TMC 278-TiDP6-C215 (Thrive)

A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus Efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral-naïve HIV-1 infected subjects. EudraCT No. 2007-002647-25.

BI 1100.1526 (Tranxition)

An open label, phase IIIb, randomized parallel group study to assess the efficacy and safety of switching HIV-1 infected patients successfully treated with a Nevirapine IR based regimen to Nevirapine XR 400 mg QD or remaining on Nevirapine IR 200 mg BID based regimen. EudraCT No. 2008-004681-55.

BI 1220.5

Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 24 weeks as combination therapy with pegylated interferon-α 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II). EudraCT No. 2008-003538-11.

112353 (TH-HIV-010 PRI)

A Phase I, randomised, placebo controlled, observer blind, multicentre study to determine safety and reactogenicity of F4co/AS01B vaccine, administered intramuscularly according to a 0, 1 Month schedule in HIV-infected subjects aged 18-55 years. EudraCT No. 2008-005009-20. 2009

CT-BI Vacc-4x 2007/1

A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART. EudraCT No. 2007-006302-13.

A4001078

Pilot Study of  novel Combination of Maraviroc + Atazanavir/Ritonavir vs Atazanavir/Ritonavir + Tenofovir/Emtrici- tabine for the treatment of Treatment naive HIV-infected patients with R5 HIV-1. EudraCT No. 2008-007038-24.

TMC 310911-TiDP-21-C201

A Phase IIa, open-label, randomized trial in treatment-naive HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 2 different b.i.d. dose regimens of TMC310911 co-administered with ritonavir. EudraCT No. 2008-008190-58

MK-7009

A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Ribavirin in Treatment-Experienced Patients with Chronic Genotype 1 Hepatitis C Virus Infection. EudraCT No. 2008-000150-12.

BI 1241.7

Safety, antiviral activity, and pharmacokinetics of BI 207127 NA administered in combination with Peg-IFN and ribavirin in chronic HCV infected patients for 4 weeks, a randomised, double-blind, placebo controlled study. EudraCT No. 2008-008292-34.

TMC435-TiDP16-C205 (Pillar)

A Phase IIb, randomized double-blind, placepo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including peginterferon alfa-2a and ribavirin in treatment-naïve genotype 1 hepatitis C-infected subjects. EudraCT No. 2008-007147-13.

TMC435-TiDP16-C206 (Aspire)

A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including PegIFNα-2a and ribavirin in HCV genotype 1 infected subjects who failed to respond or relapsed following at least 1 course of PegIFNα-2a/b and RBV therapy. EudraCT No. 2009-010590-20.

START

Strategic Timing of AntiRetroviral Treatment (START) to determine whether early ART is superior to deferred ART in delaying the occurrence of a composite outcome consisting of AIDS, non-AIDS, or death from any cause. EudraCT No. 2008-006439-12

BI 1241.21 (SOUND)

Safety, antiviral effect and pharmacokinetics of BI 207127 incombination with BI 201335 and with ribavirin for 4 (Part 1) and with or without ribavirin for 24-48 weeks (Part 2) in patients with chronic HCV genotype 1 infection (randomized, open label, Phase II). EudraCT No. 2009-018197-66

A8121014 (Fitness)

(Filibuvir in Treatment Naïve HCV Genotype 1 Subjects) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Filibuvir Plus Pegylated Interferon Alfa-2a and Ribavirin in Treatment naïve, HCV Genotype 1 Infected Subjects. EudraCT No. 2009-009214-40 2010

GS-US-216-0114

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. EudraCT No. 2009-016759-22

TMC435HPC3002

A prospective 1-year virological follow-up study in subjects previously treted in Phase IIb or Phase III study with a TMC435-containing regimen for the trearment of hepatitis C virus (HCV) infection. 2011

TMC278-TiDP6-C222

An open-label trial with TMC275 25mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide revers transcriptase inhibitors in HIV-1 infected subjects, who partici- pated in TMC278 clinical trials. EudraCT No.: 2010-021209-18

ING114467 (SINGLE)

A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/ lamivudine fixed dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naïve aduld subjects. EudraCT No. 2010-020983-39

GS-US-264-0106 (SPIRIT)

A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically-Suppressed, HIV-1 Infected Patients.  EudraCT No. 2010-023178-37

BI 1220.30

Efficacy and safety of once daily BI 201335 for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in treatment naïve patients with genotype 1 chronic hepatitis C infection (double-blinded, randomised, placebo-controlled, Phase III). EudraCT No. 2010-021716-42

BI 1220.7

A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 for 24 weeks in combination with pegylated interferon-α and ribavirin in patients who failed to a prior PegIFN / RBV treatment with genotype 1 chronic hepatitis C infection. EudraCT No.: 2010-021715-17

A4001098

A Multicenter, Randomized, Blinded, Placebo-Controled Study to evaluate the Safesty of Maraviroc in Combination with other Antiretroviral Agents in HIV-1-Infected Subjects Co-Infected with Hepatitis C and/or Hepatitis B Virus. EudraCT No. 2010-021994-35

BI 1220.48

A phase III, open-label, study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN / RBV treatment. EudraCT No.: 2011-000347-25

GS-US-264-0110 (STAR)

A Phase 3B, Randomized, Open-label Study to Evaluate theSafety and Efficacy of a Single Tablet Regimen of Emtricitabine/ Rilpivirine/Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. EudraCT No. 2010-024007-27

BI 1220.19

Safety and Efficacy of 240 mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HC V-co-infected patients. A multinational, randomised, parallel group, open-label trial. EudraCT No.: 2010-021734-59

AI438-011

A Phase IIb Randomized, Controlled, Partially Blinded Trial to Investigate Safety, Efficacy and dose-response of BMS-663068 in Treatment-experienced HIV-1Subjects, Followed by an Open-label Period on the Recommended Dose. EudraCT No.: 2011-000437-36

A4001095 (MODERN)

Multizentrische, randomisierte, doppelblinde Vergleichsstudie zu Maraviroc und Darunavir/Ritonavir versus Emtricitabin/ Tenofovir + Darunavir/Ritonavir zur Behandlung nicht antiretroviral vorbehandelter HIV-Patienten mit CCR5-tropem HIV-1. EudraCT No.: 2010-021785-30

TMC647055HPC1005

A Phase I, open label trial in genotype 1 HCV-infected subjects to determine the safety, tolerability, pharmacokinetics and antiviral activity of repeated doses of TMC647055 given in combination with telaprevir. EudraCT No.: 2011-004028-37 2012

GS-US-236-0115

A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients. 2011-004483-30

AI447-028 (DUAL)

A Phase 3 Study with Asunaprevir and Daclatasavir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligibleto P/R Subjects and Treatment-Naive Subjects with Chronic Hepatitis C Genotype 1b Infection. EudraCT No.:  2011-005446-35

CT-BI Vacc-4x/IMiD-2010/1

Randomized, Double-blind Placebo Controlled, Multicenter, Immunogenicity Pilot Study of Vacc-4x + Revlimid Versus Vacc-4x in Subjects Infected with HIV-1, on Antiretroviral Therapy (ART). EudraCT No.: 2011-001217-13

CT-BI Vacc-4x 2012/1

Re-boosting of Subjects Previously Included in the Phase IIB Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have Maintained an Adequate Response to ART. EudraCT No. 2012-002281-12

GS-US-236-0121 (STRATEGY)

A Phase 3b Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients  EudraCT No.: 2011-004963-56

MK 1439-007

Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK- 1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients. EudraCT No.: 2012-001573-93

BI 1241.30

A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype 1 chronic hepatitis C infection. EudraCT No. 2012-003534-17 2013

BI 1241.20

A phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naive Patients with Chronic Genotype 1 HCV Infection. EudraCT No.: 2012-03533-41

GS-US-292-0109

A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects. EudraCT No.: 2012-005114-20

TMC647055HPC2001

A Phase IIa, open-label trial to evaluate the safety, tolerability and efficacy of a 12 weeks combination therapy of TMC647055 and TMC435, with and without GSK2336805, with a pharmacokinetic enhancer with and without ribavirin in chronic genotype 1 hepatitis C infected patients. EudraCT No. 2012-002555-42 2014

MK 0518-292

A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir  (MK-0518) 1200 mg Once Daily Versus Raltegravir (MK-0518) 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects. EudraCT No.: 2013-001939-47

ASTRAL-3 GS-US-342-1140

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection. EudraCT-No.2014-001682-27

ASTRAL-1 GS-US-342-1138

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV. EudraCT-No. 2014-001683-35

MK 1439-018 Drive Forward

A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/ KIVEXA™in Treatment-Naïve HIV-1 Infected Subjects. EudraCT No.: 2014-001127-69

GS-US-342-1446

An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection.EudraCT-No. 2014-003898-42 2015

GS-US-380-1489

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/ Emtricitabine/ Tenofovir Alafenamide Versus Abacavir/Dolutegravir/ Lamivudine in HIV-1 Infected Antiretroviral Treatment-Naïve Adults. EudraCT No.: 2016 2015-004024-54 2016

MK 3682-011 C-Crest

A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1, GT2, and GT4 Infection. EudraCT-No.: 2014-003304-73

201637 SWORD

A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-,NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed. EudraCT No.: 2014-005148-16

MK 1439A-021 Drive Shift

A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) EudraCT No.: 2014-005550-18

MK 1439A-021 Drive Ahead

A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects. EudraCT No.: 2014-003382-17

AI468-038

A Phase 2b Randomized, Active-Controlled, Double-blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults. EudraCT No.: 2013-005487-26

TMC114FD2HTX3001 AMBER

A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/ tenofovir alafenamide once-daily single-tablet regimen versus a regimen consisting of darunavir/cobicistat fixed dose combination combined with emtricitabine/tenofovir disoproxil fumarate fixed dose combination in antiretroviral treatment-naïve human immunodeficiency virus type 1 infected subjects. EudraCT No.: 2015-000754-38

GS-US-292-1823

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV‑1 Infected Adult Subjects. EudraCT No.: 2015-002711-15

GS-US-380-1878

A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults. EudraCT No.: 2015-004011-20

GS-US-380-1844

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed. EudraCT No.: 2015-004025-14

GS-US-380-4030

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed. EudraCT No.: 2017-000308-17

206882 B-Sure

A prospective, multi-centre study (B-Sure) to evaluate long-term durability of treatment response in chronic hepatitis B participants with and without nucleos(t)die therapy who have participated in a previous bepirovirsen treatment study. EudraCT No. 2023-506867-33 

218309 B-United

A Phase 2b, multi-centre, randomised, partially placebocontrolled, observer-blind study to investigate the safety and efficacy of sequential therapy with Daplusiran/Tomligisiran followed by bepirovirsen in participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy (B-United). EudraCT No. 2024-514507-33-00

B-Well

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide
Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1)

73763989HPB2001

A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection – The REEF-1 Study. EudraCT No. 2019-000622-22

TH HBV ASO-001

A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide (ASO) against chronic Hepatitis B (CHB) followed by chronic Hepatitis B targeted immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA) therapy.

GSK4532990 – Starlight 

A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults with Alcohol-related Liver Disease (ALD)

AK-US-001-0107  Akero

A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-invasively diagnosed nonalcoholic steatohepatitis

(NASH)/nonalcoholic fatty liver disease (NAFLD). EudraCT No. 2023-505141-48-00

MGL-3196-11

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation, EudraCT Number: 2018-004012-22

337HNAS20011

A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis, EudraCT 2020-004986-38

WA43966 – Imagination

Evaluate the Efficacy And Safety Of Ro7434656, an Antisense Inhibitor Of Complement Factor B, in Patients with Primary Iga Nephropathy At High Risk of Progression

VE303-003 Restorative303 (CDif)

A randomized, double-blind, placebo-controlled phase 3 study of VE303 for prevention of recurrent clostridioides difficile infection. EudraCT No. 2023-505141-48-00

RSV 025

A Phase 3b, open-label study to evaluate the noninferiority of the immune response and to evaluate the safety of the RSVPreF3 OA investigational
vaccine in adults 18-49 years of age at increased risk for respiratory syncytial virus disease, compared to older adults ≥60 years of age.

HPV – V503-049

A Phase 3, International, Multi-center, Randomized, Double-blind, Placebocontrolled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age. EudraCT No.